<DOC>
	<DOC>NCT00769080</DOC>
	<brief_summary>The purpose of this study is to compare the 1-year adherence to upfront adjuvant AI for postmenopausal, early stage breast cancer in the two observational arms; Standard Treatment and Standard Treatment plus PSP arm after one year</brief_summary>
	<brief_title>The Performance of Patient Support Program in Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Provide signed and dated written Informed Consent Have been taking upfront AI adjuvant therapy in line with current SmPC Be capable of completing drug intake by herself Be capable of understanding Chinese Upfront adjuvant hormonal therapy by an AI to which upfront adjuvant indication has not been granted by SFDA Upfront adjuvant AI medication which has exceeded over eight weeks Previous adjuvant hormonal therapy for breast cancer lasting over 8 weeks other than AI Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>PSP</keyword>
	<keyword>Standard Treatment</keyword>
	<keyword>Standard Treatment plus PSP</keyword>
</DOC>